McGlinchey, Aidan J.; Govaere, Olivier; Geng, Dawei et al.
Metabolic signatures across the full spectrum of non-alcoholic fatty liver diseaseJHEP REPORTS. Bd. 4. H. 5. 2022
Stolze, T.; Franke, S.; Haybaeck, J. et al.
Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysisJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2022
Lederer, Ann-Kathrin; Bartsch, Fabian; Moehler, Markus et al.
Morbidity and Mortality of Neutropenic Patients in Visceral Surgery: A Narrative ReviewCELLS. Bd. 11. H. 20. 2022
Staubach, Petra; Veelen, Katrin; Zimmer, Sebastian et al.
Multidisciplinarity as the key to success Cooperation between dermatology and rheumatology to optimize patient careDERMATOLOGIE. Bd. 73. H. 11. 2022 S. 866-871
Gerber, Tiemo S.; Goeppert, Benjamin; Hausen, Anne et al.
N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the PancreasCANCERS. Bd. 14. H. 13. 2022
Foerster, Friedrich; Gairing, Simon Johannes; Mueller, Lukas et al.
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment optionsJOURNAL OF HEPATOLOGY. Bd. 76. H. 2. 2022 S. 446-457
Romero Gomez, Manuel; Sanchez, Yolanda; Garcia Rey, Silvia et al.
NASH patient's itinerary: Comparison of strategies for screening, referring and managementJOURNAL OF HEPATOLOGY. Bd. 77. 2022 S. S451-S451
Pisareva, Ekaterina; Mihalovicova, Lucia; Pastor, Brice et al.
Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNAGENOME MEDICINE. Bd. 14. H. 1. 2022
Huber, Yvonne; Foerster, Friedrich; Moehler, Markus et al.
New Studies at the University Medical Center Mainz on HCC and non-metastatic Colon CarcinomaGASTROENTEROLOGE. Bd. 17. H. 1. 2022 S. 57-58
Shitara, Kohei; Janjigian, Yelena Y.; Moehler, Markus H. et al.
Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 4. 2022